Francesco Mastropasqua

Dr. Francesco Mastropasqua

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Molecules
Verified
Journal Article
Open access
PDF file
FMFrancesco Mastropasqua
Francesco Mastropasqua
GLGert Luurtsema
Gert Luurtsema
CFCristina Filosa
Cristina Filosa
NCNicola Antonio Colabufo
Nicola Antonio Colabufo
P-Glycoprotein (P-gp, also known as MDR1 or ABCB1) is an ATP-binding cassette (ABC) transporter that actively effluxes a wide range of structurally and functionally diverse molecules, playing a crucial role in drug absorption, distribution, and excretion. P-gp is highly expressed at key biological barriers, such as the blood–brain barrier (BBB), intestine, liver, and kidneys, and it serves as a gatekeeper against xenobiotics and therapeutics. Its dysregulation is involved in multidrug resistance (MDR), epilepsy, cancer, infectious diseases, and neurodegenerative disorders. Several small molecules were synthesized using SAfIR and SAR, and, among them, [18F]MC225 showed the most promising results for in vivo human studies, with appropriate pharmacodynamics and pharmacokinetics profiles for in vivo use. [18F]MC225 is currently being employed in PHASE II human trials at the UMC Groningen, the Netherlands, in patients diagnosed with AD, PD and MCI, as well as PHASE II human trials at the Policlinico Gemelli in Rome Italy to diagnose P-gp resistant depression. Preliminary studies show that [18F]MC225 radiotracer is behaving according to the initial predictions, that is, it accurately diagnoses the aforementioned pathologies, more so than previously developed small molecules for the same goal.

5 November 2025 in Molecules
Verified
Journal Article
Open access
PDF file
FMFrancesco Mastropasqua
Francesco Mastropasqua
ALAlexander Ludwig
Alexander Ludwig
CACarmen Abate
Carmen Abate
Several pieces of evidence have demonstrated the sigma-1 receptor (S1R) as a druggable protein with important therapeutic potentials, including neurodegeneration, cancer, and neuropathic pain. The density of S1R is altered in pathological processes so that its imaging is under study for diagnostic purposes. Thus, research has been focused on the development of S1R positron emission tomography (PET) radioligands, not only as diagnostic tools but also as powerful means to assist in the drug-development process. Herein, we comprehensively review the most important S1R PET radiotracers belonging to different classes that have been developed in the last two decades. Starting from the structural modifications impacting on the S1R affinity and selectivity, we report (i) the differences in metabolism and pharmacokinetics, (ii) the in vivo behavior in different animal models, (iii) the in vitro autoradiography outcomes, and (iv) the dosimetric profiles. The successful use of the best-performing S1R PET radiotracers in the characterization of novel S1R drugs is also reported together with the approaches to assess the potential for clinical translation. What emerges from this review is that, although the development of reliable PET agents appears to be extremely challenging, these radiotracers hold incredible potential and play a fundamental role in the exploitation of S1R in health and disease.

6 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GMGabriella Rosanna Musillo
Gabriella Rosanna Musillo
Giovanni GrazianoGiovanni Graziano
Giovanni Graziano
MMMariachiara Mammone
Mariachiara Mammone
FMFrancesco Mastropasqua
Francesco Mastropasqua
MMMaria Majellaro
Maria Majellaro
CACarmen Abate
Carmen Abate
Background/Objectives: The cannabinoid receptor subtype 2 (CB2R) is an increasingly important therapeutic and diagnostic target because of its involvement in inflammation-associated disorders, including cancer and neurodegenerative diseases. CB2R biology has traditionally been investigated using radioligands, whose broader application is limited by safety, regulatory, operational, and environmental constraints. Fluorescent ligands provide a complementary approach for real-time, high-resolution analysis of receptor expression and dynamics in living systems. This study aimed to develop structurally diverse fluorescent CB2R ligands as molecular tools for investigating receptor localization, trafficking, and signaling across imaging and cell-based platforms. Methods: Probe design was based on two complementary CB2R chemotypes: the 4-oxoquinolinone scaffold of the previously reported fluorescent ligands SM15 and VM7 and the salicylamide scaffold of the reference ligand CC48. These pharmacophores were conjugated to Cyanine 5 (Cy5), Cyanine 7 (Cy7), BODIPY-TR, 7-nitrobenzo-2-oxa-1,3-diazole (NBD), or 7-nitrobenzo-2-selena-1,3-diazole (Se-NBD), generating ligands with emission profiles spanning the green to near-infrared spectral regions. Compound 2, which showed the highest CB2R affinity among the new ligands (Ki = 143.4 nM) and negligible CB1R displacement at 1 µM, was characterized photophysically in organic and aqueous media and evaluated by flow cytometry in MCF7 and PANC-1 cancer cells, which display low and high CB2R expression, respectively. Results: Compound 2 retained nanomolar CB2R affinity and exhibited detectable fluorescence in organic solvents and aqueous buffer down to nanomolar concentrations. In flow cytometry experiments, its concentration-dependent fluorescence differentiated MCF7 from PANC-1 cells. Partial displacement by the CB2R reference ligand 13, particularly in PANC-1 cells, supported a receptor-specific component of the observed labeling. Conclusions: Compound 2 combines CB2R selectivity with robust fluorescence across chemically distinct environments and can distinguish cellular models with different receptor-expression levels. These findings establish compound 2 as a promising tool for CB2R detection and provide a rational basis for developing optimized fluorescent ligands for receptor imaging, target validation, and related translational applications.